Subcutaneous delivery of monoclonal antibodies using microgel formulations
Official title: Enabling subcutaneous delivery of antibodies via microgel-based, ultra-high concentration formulations
Funded at Acousticabio, INC. · NIH-11409667 · Data updated 2026-11-12
A new approach uses tiny gel particles to deliver antibody medicines under the skin instead of through IV, aiming to be faster, more comfortable, and potentially cheaper.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Acousticabio, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | August 1, 2026 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $931,463 |
| NIH project number | 1R44TR006344-01 |
| Project ID | NIH-11409667 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include patients who rely on monoclonal antibody therapies that are typically given IV and could benefit from subcutaneous administration.
✕Less likely to help
Patients requiring IV-only regimens or those with specific contraindications to subcutaneous injections may not benefit.
What this research studies
This grant supports developing microgel-based formulations that allow monoclonal antibodies to be given subcutaneously in small volumes. The work focuses on tuning the gel properties to enable easy skin injections while preserving the antibody’s activity. Researchers will explore alginate-containing microgels to encapsulate antibodies and allow safe, effective systemic delivery after a self-administered injection. The study involves preclinical formulation optimization with a path toward simpler administration for patients who rely on antibody therapies.
Why it matters
Potential benefit: If successful, patients could receive antibody therapies via simple injections at home, reducing clinic visits and improving comfort.
How similar studies have gone: Previous efforts have shown promise with subcutaneous antibody delivery, but this project aims to enable higher-concentration formulations via microgels for practical use.
Where this research is happening
-
Acousticabio, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Foresti, Daniele — Acousticabio, INC.
- Study coordinator: Foresti, Daniele
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.